Faruqi & Faruqi, LLP Investigates Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively looking into claims concerning Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This investigation arises from a federal securities class action where investors are encouraged to consider stepping forward as lead plaintiffs before a specified deadline.
Allegations Against Regeneron Pharmaceuticals
The complaint against Regeneron alleges serious violations of federal securities laws including misleading statements and undisclosed payment arrangements. Some key points include the company's practice of paying credit card fees to distributors while ensuring that Eylea customers were not charged higher prices for using credit cards. This practice led to inflated sales figures, as Regeneron is accused of misrepresenting its sales of Eylea, a critical medication used for treating eye diseases.
Impact of DOJ's Complaint
In an important development, the U.S. Department of Justice (DOJ) filed a complaint against Regeneron under the False Claims Act. The allegations state that the company did not disclose significant discounts given to drug distributors related to reimbursed credit card fees, resulting in inflated average selling prices for Eylea. Such actions reportedly allowed Regeneron to command competitive advantages in the market for anti-VEGF medications.
Market Reaction Following Disclosure
Following the DOJ's announcements, there were notable reactions in the stock market. Specifically, Regeneron's shares dropped significantly, indicating investor concern over the company's future and potential financial implications stemming from the investigated allegations.
Shareholder Considerations
If you are a shareholder of Regeneron Pharmaceuticals, it is crucial to understand your rights in this situation. The court will appoint a lead plaintiff who has the largest financial stake in the case, and is responsible for guiding the litigation on behalf of all affected investors.
Participation in the Class Action
Investors have options—they may choose to become involved in the class action lawsuit, or they can opt to remain passive class members. Importantly, your potential recovery from any successful litigation effort will not be impacted by your decision about whether to take an active role.
Encouragement for Whistleblowers
Faruqi & Faruqi, LLP is also appealing to individuals with insights regarding Regeneron's practices. This includes whistleblowers, former employees, and shareholders who might have relevant information to share.
How to Get Involved
For those interested in learning further about the class action concerning Regeneron Pharmaceuticals, assistance is readily available. Interested parties can reach out to Faruqi & Faruqi directly for guidance on potential next steps.
Contact Information
Should you wish to consult with Faruqi & Faruqi, partners like Josh Wilson are available for communication. You can contact them via the provided telephone numbers for any inquiries related to this investigation.
Frequently Asked Questions
What led to the investigation of Regeneron Pharmaceuticals?
The investigation began due to allegations of misleading practices regarding sales of the drug Eylea, specifically related to undisclosed financial arrangements with distributors.
How can investors participate in the class action?
Investors may opt to become lead plaintiffs or remain as absent class members, with their rights to recovery unaffected by either choice.
What are the consequences of the DOJ's complaint?
The DOJ's complaint puts Regeneron's business practices under scrutiny and raises serious questions regarding their financial disclosures.
Who qualifies as a lead plaintiff?
The lead plaintiff is typically the investor holding the largest financial interest and representing the interests of the entire class in the litigation.
Where can I find more information about the class action?
Interested individuals can contact Faruqi & Faruqi, LLP directly for more detailed information regarding the ongoing investigation and legal proceedings.
